Perrigo Co Plc (PRGO) Stock Price & Analysis
Perrigo Co Plc (PRGO) fell 3.70% to USD 11.18 as of June 9, 2026 at 23:51 UTC, according to Nexqual real-time market data.
PRGO last closed at USD 11.61; the session ranged USD 10.89–11.58 on volume of 3,925,902 shares. Market capitalization is $1.55B, with a 52-week range of USD 9.23–28.44 (NYQ). Source: Nexqual, June 9, 2026 at 23:51 UTC.
Key Statistics (as of June 9, 2026 at 23:51 UTC)
| Price | USD 11.18 |
|---|---|
| Change | ▼ 3.70% (down) |
| Previous Close | USD 11.61 |
| Open | USD 11 |
| Day Range | USD 10.89 – 11.58 |
| 52-Week Range | USD 9.23 – 28.44 |
| Volume | 3,925,902 shares |
| Market Cap | $1.55B |
| Exchange | NYQ |
Technical Analysis (PRGO)
Nexqual's technical model rates PRGO "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 23:51 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.32 (neutral) |
| vs SMA50 | Below (USD 11.18) |
| MACD | -0.06 (negative) |
Analyst Ratings (PRGO)
Wall Street analysts rate PRGO "None" based on 4 analysts, with a mean price target of USD 16.5 (range USD 14–20), per Nexqual as of June 9, 2026 at 23:51 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 16.5 |
| High Target | USD 20 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 2 / 3 / 0 |
Earnings (PRGO)
| Next Earnings Date | 2026-07-31 |
|---|---|
| EPS Estimate | USD 0.36 |
| Revenue Estimate | $1.01B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.43 vs est 0.31 ▲ beat |
| 2025-12-31 | USD 0.77 vs est 0.78 ▼ miss |
| 2025-09-30 | USD 0.8 vs est 0.77 ▲ beat |
| 2025-06-30 | USD 0.57 vs est 0.59 ▼ miss |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financials & Fundamentals (PRGO)
| Total Revenue | $4.18B |
|---|---|
| Revenue Growth (YoY) | -7.20% |
| Gross Margin | +34.17% |
| Operating Margin | +3.47% |
| Profit Margin | -43.50% |
| ROE | -52.23% |
| Debt / Equity | 153.22 |
| Current Ratio | 2.72 |
| Total Cash | $357.20M |
| Total Debt | $3.83B |
| Free Cash Flow | $108.42M |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financial Health Score (PRGO)
Nexqual rates Perrigo Co Plc's overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:51 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Mixed — Gross margin 34%, operating 3% |
| Balance Sheet | Weak — $357M cash vs $3.83B debt |
| Cash Flow | Mixed — FCF $108M, slim 2.5% margin |
| Efficiency | Critical — ROE -52%, ROA 2.1% |
Ownership (PRGO)
| Insider Ownership | +0.36% |
|---|---|
| Institutional Ownership | +116.53% |
| Shares Outstanding | 138.37M |
| Float | 137.69M |
| Short % of Float | +16.03% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Leadership (PRGO)
Perrigo Co Plc is led by Eduardo Guarita Bezerra (age 49), Executive VP & CFO, per Nexqual as of June 9, 2026 at 23:51 UTC.
| Executive VP & CFO | Eduardo Guarita Bezerra (age 49) |
|---|---|
| EVP & Chief Scientific Officer | Abbie Lennox (age 44) |
| Vice President of Global Investor Relations | Eric S. Jacobson |
| Executive Vice President of Product Supply, Operations Strategy & Transformation Officer | Matthew Winterman (age 54) |
Major Backers & Investors (PRGO)
Notable institutional backers of Perrigo Co Plc include Price (T.Rowe) Associates Inc, Neuberger Berman Group, LLC, Fuller & Thaler Asset Management Inc., according to Nexqual as of June 9, 2026 at 23:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 12.87% |
| Neuberger Berman Group, LLC | 7.56% |
| Fuller & Thaler Asset Management Inc. | 5.54% |
| T. Rowe Price | 5.42% |
| Invesco | 5.38% |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 4.43% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 18.44% |
| Vanguard Group | 17.31% |
| State Street | 5.22% |
| Dimensional Fund Advisors | 4.75% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
From Perrigo Co Plc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- In North America, Perrigo is the leading store brand private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill ® and Mederma ® .
- Our unique competency is to deliver health and wellness solutions across multiple price and value tiers that improve access and choice for consumers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XRAY | DENTSPLY SIRONA Inc. | USD 10.47 | ▲ 4.7% |
| UHS | Universal Health Services, Inc. | USD 146.59 | ▲ 0.98% |
| HSIC | Henry Schein, Inc. | USD 80.03 | ▲ 3.33% |
| PVH | PVH Corp. | USD 79.92 | ▲ 2.72% |
| RMD | ResMed Inc. | USD 196.94 | ▲ 0.46% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:51 UTC. This page is informational and not investment advice.